Vir Biotechnology, Inc. Capital Expenditures Incurred but Not yet Paid
Vir Biotechnology, Inc. (VIR) reported Capital Expenditures Incurred but Not yet Paid of $1.02 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-28.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2023-02-28
- Vir Biotechnology, Inc. capital expenditures incurred but not yet paid for the quarter ending 2022-12-31 was -$5.39M, a 218.79% decline year-over-year.
- Vir Biotechnology, Inc. capital expenditures incurred but not yet paid for the quarter ending 2022-09-30 was -$2.34M, a 237.28% decline year-over-year.
- Vir Biotechnology, Inc. capital expenditures incurred but not yet paid for the quarter ending 2022-06-30 was $417.00K, a 80.21% decline year-over-year.
- Vir Biotechnology, Inc. capital expenditures incurred but not yet paid for the quarter ending 2022-03-31 was $8.34M, a 2105.82% increase year-over-year.
- Vir Biotechnology, Inc. capital expenditures incurred but not yet paid for fiscal 2022 was $1.02M, a 88.32% decline from fiscal 2021.
- Vir Biotechnology, Inc. capital expenditures incurred but not yet paid for fiscal 2021 was $8.73M, a 2185.60% increase from fiscal 2020.
- Vir Biotechnology, Inc. capital expenditures incurred but not yet paid for fiscal 2020 was $382.00K, a 57.17% decline from fiscal 2019.
- Vir Biotechnology, Inc. capital expenditures incurred but not yet paid for fiscal 2019 was $892.00K, a 55.31% decline from fiscal 2018.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2022-12-31 | -$5.39M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$7.74M derived: sum of 2 quarters · filed 2023-02-28 | -$7.32M derived: sum of 3 quarters · filed 2023-02-28 | $1.02M 10-K · filed 2023-02-28 |
| 2022-09-30 | -$2.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$1.93M derived: sum of 2 quarters · filed 2022-11-03 | $6.41M 10-Q · filed 2022-11-03 | $10.95M derived: sum of 4 quarters · filed 2023-02-28 |
| 2022-06-30 | $417.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $8.76M 10-Q · filed 2022-08-09 | $13.29M derived: sum of 3 quarters · filed 2023-02-28 | $15.00M derived: sum of 4 quarters · filed 2023-02-28 |
| 2022-03-31 | $8.34M 10-Q · filed 2022-05-05 | $12.88M derived: sum of 2 quarters · filed 2023-02-28 | $14.58M derived: sum of 3 quarters · filed 2023-02-28 | $16.69M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-12-31 | $4.54M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $6.25M derived: sum of 2 quarters · filed 2023-02-28 | $8.35M derived: sum of 3 quarters · filed 2023-02-28 | $8.73M 10-K · filed 2023-02-28 |
| 2021-09-30 | $1.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $3.81M derived: sum of 2 quarters · filed 2022-11-03 | $4.19M 10-Q · filed 2022-11-03 | $3.98M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $2.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $2.48M 10-Q · filed 2022-08-09 | $2.27M derived: sum of 3 quarters · filed 2023-02-28 | $2.56M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $378.00K 10-Q · filed 2022-05-05 | $162.00K derived: sum of 2 quarters · filed 2023-02-28 | $448.00K derived: sum of 3 quarters · filed 2023-02-28 | $239.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | -$216.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $70.00K derived: sum of 2 quarters · filed 2023-02-28 | -$139.00K derived: sum of 3 quarters · filed 2023-02-28 | $382.00K 10-K · filed 2023-02-28 |
| 2020-09-30 | $286.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $77.00K derived: sum of 2 quarters · filed 2021-11-04 | $598.00K 10-Q · filed 2021-11-04 | $1.29M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$209.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $312.00K 10-Q · filed 2021-08-05 | $1.00M derived: sum of 3 quarters · filed 2022-02-28 | $678.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $521.00K 10-Q · filed 2021-05-06 | $1.21M derived: sum of 2 quarters · filed 2022-02-28 | $887.00K derived: sum of 3 quarters · filed 2022-02-28 | $40.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $692.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $366.00K derived: sum of 2 quarters · filed 2022-02-28 | -$481.00K derived: sum of 3 quarters · filed 2022-02-28 | $892.00K 10-K · filed 2022-02-28 |
| 2019-09-30 | -$326.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | -$1.17M derived: sum of 2 quarters · filed 2020-11-10 | $200.00K 10-Q · filed 2020-11-10 | $1.82M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | -$847.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $526.00K 10-Q · filed 2020-08-11 | $2.15M derived: sum of 3 quarters · filed 2021-02-25 | |
| 2019-03-31 | $1.37M 10-Q · filed 2020-05-12 | $2.99M derived: sum of 2 quarters · filed 2021-02-25 | ||
| 2018-12-31 | $1.62M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $2.00M 10-K · filed 2021-02-25 | ||
| 2018-09-30 | $377.00K 10-Q · filed 2019-11-19 | |||
| 2017-12-31 | $1.89M 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |